Beta cell function and insulin sensitivity during elexacaftor/tezacaftor/ivacaftor therapy in people with cystic fibrosis
ETI therapy was not associated with reversal of existing glucose tolerance abnormalities but may contribute to preservation of beta-cell function and insulin sensitivity. This is supported by stable DC values over time, in contrast to the progressive decline typically observed in CF populations.
Authors
- Riccardo C. Bonadonna (ORCID: https://orcid.org/0000-0002-9809-1005)
- Gianfranco Alicandro (ORCID: https://orcid.org/0000-0002-0430-2714)
- Irene Cogliati
- Maddalena Trombetta (ORCID: https://orcid.org/0000-0002-0825-1117)
- Valeria Daccò (ORCID: https://orcid.org/0000-0002-7497-9165)
- L. Zazzeron
- Emanuela Orsi
- Maria Linda Boselli
- Andrea Gramegna
- Francesco Blasi
- Valeria Grancini
- Giovanna Mantovani
Institutions
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Ospedale Maggiore (IT)
- University Hospital Foundation (CA)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2026-02-27
- DOI
- https://doi.org/10.3389/fendo.2026.1774728
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Università degli Studi di Milano
- Dipartimenti di Eccellenza
- Ministero della Salute
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico